-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Satellite Symposia

Friday, December 4, 2020

Friday | top

7:00 AM-10:00 AM

A Case-based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis
Acute Myeloid Leukemia: Using Available Evidence and Guidelines to Make Sense of a Rapidly Evolving Treatment Paradigm
Advances in Diagnosis and Management of Myelodysplastic Syndromes
An Optimized Approach to Sickle Cell Disease Care in a New Era of Treatment
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Multiple Myeloma (Part 1 of a 4-Part Series)
Managing Myeloma: Where We Are, Where We’re Going, and Where We SHOULD Be Going (Time to Choose Sides!)
Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics
Mapping the New Era in CLL Management: Precision Medicine and Patient Perspectives in Treatment-Naïve and Relapsed Disease
Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine
Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model
Understanding Cold Agglutinin Disease: How Do Emerging Treatment Options Have the Potential to Transform Patient Outcomes?

11:00 AM-2:00 PM

Accelerating Toward a Cure for Myeloma: Emerging Data, New Agents, and an Evolving Treatment Paradigm
Advances in GvHD: Expert Guidance on the Current Treatment Landscape, Optimizing Prophylaxis, and Integrating Novel Therapies
Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL
Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)
Advances in Therapy for Inherited Non-Malignant Blood Disorders: Focus on Sickle Cell Disease and Hemophilia.
D is for Diagnosis: Detecting and Treating Rare Disorders in Hematologic Practice
Individualizing Treatment Plans and Optimizing Outcomes for Patients with MF and PV: Stories Behind The Science
MEDICAL CROSSFIRE®: BRIDGING UNMET NEEDS WITH EMERGING DATA IN RELAPSED/REFRACTORY DLBCL TO IMPROVE PATIENT OUTCOMES
Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
New Targets, New Data, New Guidelines: Assessing Treatment Options to Personalize Care in B-Cell Lymphomas
Taking Action with Minimal Residual Disease: Technique, Role, and Utilization of MRD to Improve Outcomes in Patients with Hematologic Malignancies
T-Cell Lymphoma Tumor Board: Application of Novel Agents for the Treatment of PTCL and CTCL
The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets into Clinical Practice

3:00 PM-6:00 PM

Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes
Adopting New Approaches for Relapsed/Refractory Follicular Lymphoma
A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
Applying Data to Practice: The Role of BTK Inhibitors for the Treatment of CLL
Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Acute Myeloid Leukemia (Part 3 of a 4-Part Series)
Contemporary Management of Hemophilia A: Expert Guidance to Improve Patient Outcomes
Advances in CAR T-Cell Therapy: What Does the Future Look Like?
Evolving the Standard of Care: Rethinking the Treatment Paradigm for Iron Deficiency Anemia
Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma
How to Do It™ Interactive Workshop: Taking Action With Clinical Advances in Chronic Lymphocytic Leukemia
Key Considerations: Advances in Gene Therapy for Hemophilia
New Agents and Therapeutic Strategies in Beta-Thalassemia
Sickle Cell Disease: Targeting Complications to Improve Long-term Implications
Transforming the Treatment Paradigm for Patients With MDS

7:00 PM-10:00 PM

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Patients with Hodgkin and Non-Hodgkin Lymphoma (Part 4 of a 4-Part Series)
Leveraging Clinical Data and Trials to Inform Treatment for Patients with GvHD: An Expert Case-Based Discussion
Improving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors
State-of-the-Art Care in Relapsed/Refractory Multiple Myeloma: Novel Targets, Combinations, and Treatment Approaches